Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. [electronic resource]
Producer: 20061204Description: 1747-60 p. digitalISSN:- 1360-8185
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Caspase 3 -- metabolism
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- DNA Fragmentation -- drug effects
- Dose-Response Relationship, Drug
- Enzyme Activation -- drug effects
- Etoposide -- analogs & derivatives
- Humans
- Isoxazoles -- pharmacology
- K562 Cells
- Leflunomide
- Leukemia, Erythroblastic, Acute -- drug therapy
- MAP Kinase Kinase 4 -- metabolism
- MAP Kinase Signaling System -- drug effects
- Mitogen-Activated Protein Kinase 8 -- metabolism
- NF-kappa B -- metabolism
- Organophosphorus Compounds -- pharmacology
- Phosphatidylinositol 3-Kinases -- metabolism
- Proto-Oncogene Proteins c-akt -- metabolism
- Signal Transduction -- drug effects
- Staurosporine -- pharmacology
- p38 Mitogen-Activated Protein Kinases -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.